SEC Stock Data Quick Answer Zomedica Corp. reported Stockholders Equity of $115.40 million for fiscal year 2025. Zomedica Corp. Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 $115.40M -41.0% 2024 $195.66M -18.5% 2023 $240.02M -10.2% 2022 $267.39M -1.3% 2021 $270.89M +430.4% 2020 $51.07M +2337.2% 2019 $2.10M -42.7% 2018 $3.66M -16.6% 2017 $4.39M +14.4% 2016 … Read more
Quick Answer Zomedica Corp. reported Cash and Equivalents of $9.02 million for fiscal year 2025. Zomedica Corp. Cash and Equivalents — Annual History Fiscal Year Cash and Equivalents YoY Change 2025 $9.02M +28.4% 2024 $7.02M -45.8% 2023 $12.95M -52.7% 2022 $27.40M -85.9% 2021 $194.95M +214.5% 2020 $61.99M +12041.3% 2019 $510.6K -73.7% 2018 $1.94M -43.7% 2017 … Read more
Quick Answer Zomedica Corp. reported Total Assets of $127.04 million for fiscal year 2025. Zomedica Corp. Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $127.04M -38.7% 2024 $207.36M -18.1% 2023 $253.20M -9.4% 2022 $279.61M -0.3% 2021 $280.40M +323.9% 2020 $66.14M +1481.3% 2019 $4.18M -30.7% 2018 $6.03M +15.7% 2017 $5.22M +14.0% 2016 … Read more
Quick Answer Zomedica Corp. reported Diluted EPS of $0.08 per share (loss) for fiscal year 2025. Zomedica Corp. Diluted EPS — Annual History Fiscal Year Diluted EPS YoY Change 2025 -$0.08 -60.0% 2024 -$0.05 -25.0% 2023 -$0.04 -135.3% 2022 -$0.02 — Quarterly Diluted EPS Quarter Ending Diluted EPS YoY QoQ September 30, 2025 -$0.01 +0.0% … Read more
Quick Answer Zomedica Corp. reported Net Income of -$81.86 million for fiscal year 2025. Zomedica Corp. Net Income — Annual History Fiscal Year Net Income YoY Change 2025 -$81.86M -74.2% 2024 -$46.98M -36.1% 2023 -$34.53M -102.9% 2022 -$17.02M +7.4% 2021 -$18.38M -8.7% 2020 -$16.91M +14.5% 2019 -$19.78M -18.8% 2018 -$16.65M -106.4% 2017 -$8.07M -40.5% 2016 … Read more
Quick Answer Zomedica Corp. reported Revenue (ASC 606) of $32.03 million for fiscal year 2025. Zomedica Corp. Revenue (ASC 606) — Annual History Fiscal Year Revenue (ASC 606) YoY Change 2025 $32.03M +17.4% 2024 $27.29M +8.3% 2023 $25.19M +33.0% 2022 $18.93M +358.0% 2021 $4.13M — 2020 $0.00 — Quarterly Revenue (ASC 606) Quarter Ending Revenue … Read more
Quick Answer Zomedica Corp. reported Total Revenue of $32.03 million for fiscal year 2025. Zomedica Corp. Total Revenue — Annual History Fiscal Year Total Revenue YoY Change 2025 $32.03M +17.4% 2024 $27.29M +8.3% 2023 $25.19M +33.0% 2022 $18.93M +358.0% 2021 $4.13M — 2020 $0.00 — Quarterly Total Revenue Quarter Ending Total Revenue YoY QoQ September … Read more
Quick Answer Zomedica Corp. reported Total Revenue of $32.03 million for fiscal year 2025. Zomedica Corp. — Key Financials by Year Metric 2025 2024 2023 2022 2021 2020 Total Revenue $32.03M+17.4% $27.29M+8.3% $25.19M+33.0% $18.93M+358.0% $4.13M $0.00 Revenue (ASC 606) $32.03M+17.4% $27.29M+8.3% $25.19M+33.0% $18.93M+358.0% $4.13M $0.00 Net Income -$81.86M-74.2% -$46.98M-36.1% -$34.53M-102.9% -$17.02M+7.4% -$18.38M-8.7% -$16.91M+14.5% Diluted EPS … Read more
Quick Answer Zentalis Pharmaceuticals, Inc. reported Shares Outstanding of 69.09 million shares for fiscal year 2025. Zentalis Pharmaceuticals, Inc. Shares Outstanding — Annual History Fiscal Year Shares Outstanding YoY Change 2025 69.09M -3.1% 2024 71.28M +0.7% 2023 70.77M +19.4% 2022 59.28M +30.3% 2021 45.49M +10.8% 2020 41.04M +691.1% 2017 5.19M — Quarterly Shares Outstanding Quarter … Read more
Quick Answer Zentalis Pharmaceuticals, Inc. reported Operating Income of -$152.81 million for fiscal year 2025. Zentalis Pharmaceuticals, Inc. Operating Income — Annual History Fiscal Year Operating Income YoY Change 2025 -$152.81M +20.1% 2024 -$191.19M +36.2% 2023 -$299.51M -31.8% 2022 -$227.29M -5.0% 2021 -$216.54M -82.3% 2020 -$118.79M -153.6% 2019 -$46.84M — Quarterly Operating Income Quarter Ending … Read more